CURE vs RXL: Leverage, Returns & Decay
Over three months to Nov 13, 2026, against its daily multiple, compounded, CURE finished 3.3 points short and RXL 1.8 points short.
- Return gap
- +20.4 pts1 year to Nov 13, 2026: CURE ahead, total return
- Fee gap
- 0.01 ptsA year: CURE 0.94%, RXL 0.95%, per filings dated Mar 3, 2026 and Sep 25, 2026
- Overlap
- –No book read for both funds
- Net flow
- −$7m / +$2mCURE / RXL, Oct 13, 2026 to Nov 12, 2026, daily basis
Compare two other funds
Growth of 100
Drawn from the numbers on this page. Growth of 100, both funds, distributions reinvested
CURE +65.7%, RXL +45.3%: CURE +20.4 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.
ShareUse this comparison
Client brief:
The two-page PDF for this pair is coming. Save the comparison to follow its changes. Free. It needs an email sign-in, once.
Cost to trade
Hypothetical. A $10,000 order in RXL costs about $7.00 one way and $14.00 in and out, at a median spread of 0.14%. The 0.14% spread is RXL’s 30-day median, from ProShares (fund page).
Fees over time
Hypothetical. $10,000 in RXL for 10 years at 0.95% a year costs about $1,542 in fees and lost growth; CURE at 0.94% would cost $1,526. Assumes 6% a year before fees, a sample rate, not a forecast.
How each fund moved
CURE returned +38.2% while 3 times XLV's move would have been +39.9%. Data from Aug 14, 2026 to Nov 13, 2026.
Data from Aug 14, 2026 to Nov 13, 2026.RXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.
RXL returned +25.3% while 2 times XLV's move would have been +26.6%. Data from Aug 14, 2026 to Nov 13, 2026.IQ Leverage Score
How closely it delivered its daily multiple over 3 months, ranked against 31 leveraged ETFs at 3x, over three months and 498 leveraged ETFs at 2x, over three months. 100 is best.
RXL scores higher · Did it keep up with its own daily multiple, compounded day by day, over three months?
CURE among the 31 leveraged ETFs at 3x, over three months
RXL among the 498 leveraged ETFs at 2x, over three months
A percentile among the 31 leveraged ETFs at 3x, over three months. RXL is a percentile among the 498 leveraged ETFs at 2x, over three months, a different set, so the two marks are not on one scale. Three months only, against the fund's own daily multiple; a different quarter can rank it very differently.
Key numbers
CURE costs 0.01 points a year less; their one-year returns differ by 20.4 points; CURE is 1.8 times larger.
Pair scorecard
Open the table
Points (pts) are percentage points.
| Total return, 1 year | +65.7% | +45.3% |
|---|---|---|
| What its daily multiple gave, 3 months | 41.5% | 27.1% |
| What the underlying did, 3 months | XLV 13.3% | XLV 13.3% |
| What the underlying did, 3 months | XLV 13.3% | XLV 13.3% |
| What it tracks | Healthcare | Health Care |
| Expense ratio | 0.94% | 0.95% |
| Net assets, as of Nov 12, 2026 | $209m | $117m |
| Holdings in common | not published |
The numbers behind it
Net assets: $209m on Nov 12, 2026 for Direxion Daily Healthcare Bull 3X ETF, and $118m on Nov 13, 2026 for ProShares Ultra Health Care.
Side by side
Open the table
| Fund | Direxion Daily Healthcare Bull 3X ETF · Aims to return three times the daily move of health care (XLV) | ProShares Ultra Health Care · Aims to return twice the daily move of health care (XLV) |
| Issuer | Direxion | ProShares |
| Sets out to return | +3x | +2x |
| Underlying asset | XLV | XLV |
| Segment | sector | sector |
| Fund returned, 3 months | +38.2% | +25.3% |
| Underlying returned, over that window | +13.3% | +13.3% |
| What the stated multiple implies, over that window | +39.9% | +26.6% |
| Difference from stated, over that window | −1.7 pts | −1.3 pts |
| Fund returned, 1 year | +65.7% | +45.3% |
| Difference from stated, over that window | −11.4 pts | −6.1 pts |
| Underlying volatility | 19% | 19% |
| Difference over the days both have traded | no shared window | −1.3 pts |
| Expense ratio | 0.94% | 0.95% |
| First traded | Jun 15, 2011 | Feb 1, 2007 |
| Net assets, CURE as of Nov 12, 2026 and RXL as of Nov 13, 2026 | $209m | $118m |
As of Nov 13, 2026. Source: ETFIQ.
Window by window
Open the full table
| 1 month | +25.9% | +16.8% | +25.8% | +17.2% | +0.1 pts | −0.4 pts |
|---|---|---|---|---|---|---|
| 3 months | +38.2% | +25.3% | +39.9% | +26.6% | −1.7 pts | −1.3 pts |
| 6 months | +104.8% | +64.6% | +93.6% | +62.4% | +11.2 pts | +2.2 pts |
| 1 year | +65.7% | +45.3% | +77.1% | +51.4% | −11.4 pts | −6.1 pts |
| 3 years | +117.4% | +87.6% | +165.6% | +110.4% | −48.2 pts | −22.8 pts |
| Since launch (Not the same days: CURE Jun 2011 · RXL Feb 2007) | +3,894.1% | +1,797.2% | not meaningful | not meaningful | not meaningful | not meaningful |
From Jun 2011 to Nov 2026, CURE returned more: +3,913.0% to +1,874.7%. RXL swung less: 32.5% to 47.6%. RXL fell less at its worst: −46.5% to −63.2%.
Full scorecard
Open the full table
| Total return | +3,913.0% | +1,874.7% | CURE | Price change plus distributions, reinvested. | |
| Annualized | +27.0% | +21.3% | CURE | Total return as a yearly rate. | |
| Price return | +3,482.3% | +1,726.5% | CURE | Price change alone, distributions left out. | |
| Volatility | 47.6% | 32.5% | RXL | Spread of weekly returns, annualized. Lower is steadier. | |
| Downside deviation | 32.3% | 22.2% | RXL | Like volatility, counting only weeks below the Treasury bill rate. | |
| Max drawdown | −63.2% | −46.5% | RXL | Deepest fall from a high to the low after it. | |
| Upside capture | 734.6% | 315.4% | 100.0% | CURE | Share of its benchmark's rise caught in the weeks it rose. |
| Downside capture | 159.3% | 143.4% | 100.0% | RXL (slight) | Share of its benchmark's fall taken in the weeks it fell. Lower is better. |
| Beta | 2.97 | 2.02 | 1.00 | RXL lower | How far it moves for each 1% its benchmark moves. |
| R squared | 0.99 | 0.99 | 1.00 | Not an edge | Share of its weekly moves its benchmark explains. |
| Sharpe | 0.71 | 0.71 | Tie | Return above Treasury bills per unit of volatility. | |
| Sortino | 1.05 | 1.03 | Tie | Return above Treasury bills per unit of downside deviation. | |
| Treynor | 0.114 | 0.114 | 0.122 | Tie | Return above Treasury bills per unit of beta. |
| Calmar | 0.43 | 0.46 | RXL (slight) | Annualized return divided by the max drawdown. | |
| Benchmark | XLV | XLV | XLV | The ETF each fund is measured against. | |
| Alpha | −2.5% a year | −1.7% a year | 0.0% | CURE significant | Yearly return beyond what its beta to the benchmark predicts. |
| Alpha t-stat | −2.23 | −1.88 | Not an edge | How sure the alpha is. Below 2, it could be chance. | |
| Alpha range | −4.6% to −0.3% | −3.5% to +0.1% | RXL's includes zero | The 95% range for the yearly alpha. | |
| Information ratio | 0.68 | 0.65 | CURE (slight) | Return against its benchmark per unit of tracking error. | |
| Tracking error | 31.8% | 16.7% | 0.0% | Not an edge | How far weekly returns stray from the benchmark, annualized. |
More
Computed by ETFIQ from Tiingo daily prices and ETFIQ's distribution records, 803 weekly returns. Cash rate: the 13-week Treasury bill.
About CURE
Over the three months to Nov 13, 2026, CURE returned 38.2%, against 41.5% for three times XLV's daily moves. Read the multiple against the whole window instead and 3 times XLV's 13.3% implies +39.9%, which makes CURE look 1.7 points short. That is not the fund's objective, which is daily. Of that 1.7, daily compounding is +1.6 points, which any 3 times fund would show over the same path, and the fund itself is −3.3 points against 3 times each day's move, compounded. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer periods the daily results compound, so the total is not +3 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run. XLV moved at 19% annualized over that window. The more it moves, the further the two numbers separate.
About RXL
Over the three months to Nov 13, 2026, RXL returned 25.3%, against 27.1% for twice XLV's daily moves. Read the multiple against the whole window instead and 2 times XLV's 13.3% implies +26.6%, which makes RXL look 1.3 points short. Of that 1.3, daily compounding is +0.5 points, which any 2 times fund would show over the same path, and the fund itself is −1.8 points against 2 times each day's move, compounded. RXL aims to return +2 times XLV's move each day, then resets. Over longer periods the daily results compound, so the total is not +2 times the period's move: it is lower after a fall and recovery, and can be higher in a steady run.
Questions people ask
Which came closer to its daily multiple, CURE or RXL?
Over the window to Nov 13, 2026, CURE finished 1.7 points from what its multiple implies and RXL finished 1.3 points from its own, so RXL came closer. Neither number predicts the next window: it depends on how much the underlying moves about.
Are CURE and RXL levered on the same thing?
Yes. Both are levered on health care, CURE at +3 times and RXL at +2 times the daily move.
Which one decays faster, CURE or RXL?
Decay follows how much the underlying moves about. Over this window CURE’s moved at 19% annualized and RXL’s at 19%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.
Can I hold CURE or RXL for a year?
Both reset every day, so the multiple in the name applies to a single day, and daily results compound. Over a year the total is not the multiple times the year’s move; after a fall and recovery it is lower.
Other comparisons
Sources
More
Links are sources, not endorsements. A comparison is not a recommendation.
Copy and cite
Cite this pageCitation, APA and Markdown
ETFIQ, CURE against RXL, data as of Nov 13, 2026. https://etfiq.com/compare/leverage/cure-vs-rxl
ETFIQ. (Nov 13, 2026). CURE against RXL. Retrieved from https://etfiq.com/compare/leverage/cure-vs-rxl
[CURE against RXL (ETFIQ, Nov 13, 2026)](https://etfiq.com/compare/leverage/cure-vs-rxl)
Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.